CONFIDENTIAL TREATMENT REQUESTED] FINANCING AGREEMENTFinancing Agreement • March 4th, 2005 • Cell Therapeutics Inc • Pharmaceutical preparations
This Financing Agreement (this “Agreement”), is entered into as of December 21, 2004 (the “Effective Date”), between, on the one hand, Cell Therapeutics, Inc., a Washington corporation, with a principal place of business at 501 Elliott Avenue West, Suite 400, Seattle, WA 98119 (“CTI”), and PolaRx Biopharmaceuticals, Inc., a Delaware corporation and a wholly-owned subsidiary of CTI (“PolaRx”) (together CTI and PolaRx are referred to as the “CTI Parties” and individually as a “CTI Party”); and, on the other hand, PharmaBio Development, Inc., a North Carolina corporation, with a principal place of business at 4709 Creekstone Drive, Suite 200, Durham, NC, 27703 (“PharmaBio”). The CTI Parties and PharmaBio are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
FORM OF STANDARD NONQUALIFIED STOCK OPTION AGREEMENT] CELL THERAPEUTICS, INC. NOVUSPHARMA S.p.A. STOCK OPTION PLAN NONQUALIFIED STOCK OPTION AGREEMENT Grant #Nonqualified Stock Option Agreement • March 4th, 2005 • Cell Therapeutics Inc • Pharmaceutical preparations
